Detalles de la búsqueda
1.
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study.
Br J Haematol
; 2024 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38719214
2.
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the ß2 and ß1 subunits of the proteasome complex.
Haematologica
; 108(6): 1628-1639, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36727403
3.
Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma.
Hematol Oncol
; 40(2): 202-211, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34796520
4.
Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma.
Eur J Haematol
; 104(4): 352-355, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31922303
5.
Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness.
Blood
; 134(10): 836-840, 2019 09 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31340981
6.
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.
Int J Immunopathol Pharmacol
; 34: 2058738420980258, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33353443
7.
Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease.
Cancers (Basel)
; 12(4)2020 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-32340174
Resultados
1 -
7
de 7
1
Próxima >
>>